Company intelligence / Profile preview

SCG Cell Therapy

Ownership: Private
Employees: ~200
Development stage: Phase 1

Overview

SCG101, their lead autologous HBsAg-specific TCR-T cell therapy, showed 100% HBsAg+ hepatocyte eradication and 74.5% HCC tumor reduction with a single dose in clinical trials. The therapy has received approvals from FDA, NMPA, and HSA for clinical trials in patients with HBV-related HCC.

Therapeutic areas: OncologyInfectious Diseases
Modalities: T cell therapiesbispecific antibodiestherapeutic vaccinesRNA-based therapeutics
Industry: Biotech

Drug pipeline

5 assets

SCG142

4 more assets in the full pipeline.

Request access →

Partnerships

Singapore Health Sciences Authority (HSA)Agency for Science, Technology and Research (A*STAR)Advanced Cell Therapy and Research Institute SingaporeA*STAR's Bioprocessing Technology InstituteInstitute of Molecular and Cell Biology

Beyond the preview

Go deeper on SCG Cell Therapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCG Cell Therapy.

Explore the full profile